What is the Purpose of this Study?
This study focuses on individuals who have been diagnosed with high-grade prostate cancer localized to one lobe and are considering high-intensity, focused ultrasound (HIFU) therapy or who have elected to undergo radical prostatectomy. The purpose of the study is to evaluate the usefulness of new imaging technologies, DWI MRI and 18F-PSMA PET-MRI, in detecting biopsy-proven prostate cancers not seen on standard magnetic resonance imaging technologies (MRI).
DWI MRI is a high-resolution, diffusion-weighted MRI imaging technique. 18F-PSMA (prostate-specific membrane antigen) PET-MRI is an imaging method that uses a radioactive drug called 18F-DCFPyL Injection. Researchers believe that the combination of DWI MRI and 18F-PSMA PET-MRI may improve diagnostic accuracy in detecting prostate cancer lesions. The use of 18F-DCFPyL in this study is investigational.
Eligibility
- Biopsy consisting of ≥ 10 tissue cores sampled
- PSA <20 ng/mL (for HIFU arm only)
- cT1-cT2c
- Either overall Gleason score > 7 with Gleason grade 4 or 5 component localized to one lobe (i.e. right or left) OR overall Gleason score 6 with > half of systematic biopsy cores positive and > 50% of core involvement in at least one core (for HIFU arm only)
Where can I participate?
Cedars-Sinai Cancer at SOCC
More about this Clinical Trial
What is the full name of this clinical trial?
IIT2020-14-DAGNOLO-HIFU: High-Resolution, 18F-PSMA PET-MRI for Mapping Prostate Cancer in Patients Considering Focal High-Intensity Focused Ultrasound Therapy or Radical Prostatectomy